Insiders Immutep Limited

Equities

Delayed Australian S.E. Other stock markets 01:13:04 10/05/2024 BST			5-day change	1st Jan Change
0.4675 ^AUD	+0.54%		+11.31%	+35.51%

05-02	Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	CI
05-02	Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	MT

Encouraging results for Immutep's cancer therapies	03-25	FI
Immutep Limited Appoints Florian Vogl as Chief Medical Officer	26/04/23	CI
Immutep Limited Announces Changes to the Board	10/04/23	CI
Immutep Appoints Frederic Triebel as Executive Director	12/09/22	CI
Immutep Limited Announces Executive Changes	17/05/22	CI
Immutep Limited Appoints Lucy Turnbull as Non-Executive Director	24/02/22	CI
Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director	01/02/22	CI
Immutep Limited Announces Executive Changes	04/01/21	CI
Prima BioMed Ltd will Change its Name to Immutep Ltd	01/12/17	CI
Prima Biomed Limited Announces Cessation of Lucy Turnbull as Director	22/11/17	CI
Immutep Limited Announces Cessation of Mr. Albert Wong as Director	22/11/17	CI
Prima BioMed Ltd. Appoints Grant Chamberlain as Non-Executive Director	20/08/17	CI
Prima Biomed Ltd. Announces Formation of Clinical Advisory Board	01/06/17	CI
Prima Biomed Ltd. Appoints Jay Campbell as General Manager, US Operations	06/03/17	CI
Prima Biomed Ltd. Announces Executive Changes	08/03/16	CI
Stuart Roberts Appoints Stuart Roberts as Global Head of Investor Relations	19/01/15	CI
Frédéric Triebel Joins Prima Biomed Ltd as its New Chief Scientific Officer and Chief Medical Officer	17/12/14	CI
Prima Biomed Ltd. Announces Executive Changes	09/07/14	CI
Prima BioMed Ltd Appoints Professors Eric Pujade-Lauraine, Christian Marth and Ignace Vergote to its Clinical Advisory Board	25/03/14	CI
Bradley J. Monk to Join Prima Biomed's Clinical Advisory Board	20/02/14	CI

No results for this search